Literature DB >> 36228619

Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.

Delphine Planas1, Isabelle Staropoli2, Françoise Porot2, Florence Guivel-Benhassine2, Lynda Handala3, Matthieu Prot4, William-Henry Bolland5, Julien Puech6, Hélène Péré7, David Veyer7, Aymeric Sève8, Etienne Simon-Lorière4, Timothée Bruel9, Thierry Prazuck8, Karl Stefic3, Laurent Hocqueloux8, Olivier Schwartz10.   

Abstract

BACKGROUND: Since early 2022, Omicron BA.1 has been eclipsed by BA.2, which was in turn outcompeted by BA.5, which displays enhanced antibody escape properties.
METHODS: Here, we evaluated the duration of the neutralizing antibody (Nab) response, up to 18 months after Pfizer BNT162b2 vaccination, in individuals with or without BA.1/BA.2 breakthrough infection. We measured neutralization of the ancestral D614G lineage, Delta, and Omicron BA.1, BA.2, and BA.5 variants in 300 sera and 35 nasal swabs from 27 individuals.
FINDINGS: Upon vaccination, serum Nab titers were decreased by 10-, 15-, and 25-fold for BA.1, BA.2, and BA.5, respectively, compared with D614G. We estimated that, after boosting, the duration of neutralization was markedly shortened from 11.5 months with D614G to 5.5 months with BA.5. After breakthrough, we observed a sharp increase of Nabs against Omicron subvariants, followed by a plateau and a slow decline after 5-6 months. In nasal swabs, infection, but not vaccination, triggered a strong immunoglobulin A (IgA) response and a detectable Omicron-neutralizing activity.
CONCLUSIONS: BA.5 spread is partly due to abbreviated vaccine efficacy, particularly in individuals who were not infected with previous Omicron variants. FUNDING: Work in O.S.'s laboratory is funded by the Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito, and IDISCOVR, Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases' (grant no. ANR-10-LABX-62-IBEID), HERA european funding and the NIH PICREID (grant no U01AI151758).
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BA.5; IgA; IgG; Omicron; SARS-Cov-2; Translation to patients; breakthrough; mucosal immunity; neutralization; vaccine; variants

Year:  2022        PMID: 36228619      PMCID: PMC9533668          DOI: 10.1016/j.medj.2022.09.010

Source DB:  PubMed          Journal:  Med (N Y)        ISSN: 2666-6340


  43 in total

1.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.

Authors:  Delphine Planas; Timothée Bruel; Ludivine Grzelak; Florence Guivel-Benhassine; Isabelle Staropoli; Françoise Porrot; Cyril Planchais; Julian Buchrieser; Maaran Michael Rajah; Elodie Bishop; Mélanie Albert; Flora Donati; Matthieu Prot; Sylvie Behillil; Vincent Enouf; Marianne Maquart; Mounira Smati-Lafarge; Emmanuelle Varon; Frédérique Schortgen; Layla Yahyaoui; Maria Gonzalez; Jérôme De Sèze; Hélène Péré; David Veyer; Aymeric Sève; Etienne Simon-Lorière; Samira Fafi-Kremer; Karl Stefic; Hugo Mouquet; Laurent Hocqueloux; Sylvie van der Werf; Thierry Prazuck; Olivier Schwartz
Journal:  Nat Med       Date:  2021-03-26       Impact factor: 53.440

2.  Humoral and cellular immune memory to four COVID-19 vaccines.

Authors:  Zeli Zhang; Jose Mateus; Camila H Coelho; Jennifer M Dan; Carolyn Rydyznski Moderbacher; Rosa Isela Gálvez; Fernanda H Cortes; Alba Grifoni; Alison Tarke; James Chang; E Alexandar Escarrega; Christina Kim; Benjamin Goodwin; Nathaniel I Bloom; April Frazier; Daniela Weiskopf; Alessandro Sette; Shane Crotty
Journal:  Cell       Date:  2022-05-27       Impact factor: 66.850

3.  Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.

Authors:  Nicole P Hachmann; Jessica Miller; Ai-Ris Y Collier; John D Ventura; Jingyou Yu; Marjorie Rowe; Esther A Bondzie; Olivia Powers; Nehalee Surve; Kevin Hall; Dan H Barouch
Journal:  N Engl J Med       Date:  2022-06-22       Impact factor: 176.079

4.  Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Authors:  Aekkachai Tuekprakhon; Rungtiwa Nutalai; Aiste Dijokaite-Guraliuc; Daming Zhou; Helen M Ginn; Muneeswaran Selvaraj; Chang Liu; Alexander J Mentzer; Piyada Supasa; Helen M E Duyvesteyn; Raksha Das; Donal Skelly; Thomas G Ritter; Ali Amini; Sagida Bibi; Sandra Adele; Sile Ann Johnson; Bede Constantinides; Hermione Webster; Nigel Temperton; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Derrick Crook; Andrew J Pollard; Teresa Lambe; Philip Goulder; Neil G Paterson; Mark A Williams; David R Hall; Elizabeth E Fry; Jiandong Huo; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2022-06-09       Impact factor: 66.850

5.  Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost.

Authors:  Frauke Muecksch; Zijun Wang; Alice Cho; Christian Gaebler; Tarek Ben Tanfous; Justin DaSilva; Eva Bednarski; Victor Ramos; Shuai Zong; Brianna Johnson; Raphael Raspe; Dennis Schaefer-Babajew; Irina Shimeliovich; Mridushi Daga; Kai-Hui Yao; Fabian Schmidt; Katrina G Millard; Martina Turroja; Mila Jankovic; Thiago Y Oliveira; Anna Gazumyan; Marina Caskey; Theodora Hatziioannou; Paul D Bieniasz; Michel C Nussenzweig
Journal:  Nature       Date:  2022-04-21       Impact factor: 69.504

6.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.

Authors:  Wilfredo F Garcia-Beltran; Kerri J St Denis; Angelique Hoelzemer; Evan C Lam; Adam D Nitido; Maegan L Sheehan; Cristhian Berrios; Onosereme Ofoman; Christina C Chang; Blake M Hauser; Jared Feldman; Alex L Roederer; David J Gregory; Mark C Poznansky; Aaron G Schmidt; A John Iafrate; Vivek Naranbhai; Alejandro B Balazs
Journal:  Cell       Date:  2022-01-06       Impact factor: 41.582

7.  Plasma Neutralization of the SARS-CoV-2 Omicron Variant.

Authors:  Fabian Schmidt; Frauke Muecksch; Yiska Weisblum; Justin Da Silva; Eva Bednarski; Alice Cho; Zijun Wang; Christian Gaebler; Marina Caskey; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz
Journal:  N Engl J Med       Date:  2021-12-30       Impact factor: 91.245

8.  Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.

Authors:  Panke Qu; Julia Faraone; John P Evans; Xue Zou; Yi-Min Zheng; Claire Carlin; Joseph S Bednash; Gerard Lozanski; Rama K Mallampalli; Linda J Saif; Eugene M Oltz; Peter J Mohler; Richard J Gumina; Shan-Lu Liu
Journal:  N Engl J Med       Date:  2022-06-15       Impact factor: 176.079

9.  Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.

Authors:  Dinah V Parums
Journal:  Med Sci Monit       Date:  2022-07-01

10.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.

Authors:  Qian Wang; Yicheng Guo; Sho Iketani; Manoj S Nair; Zhiteng Li; Hiroshi Mohri; Maple Wang; Jian Yu; Anthony D Bowen; Jennifer Y Chang; Jayesh G Shah; Nadia Nguyen; Zhiwei Chen; Kathrine Meyers; Michael T Yin; Magdalena E Sobieszczyk; Zizhang Sheng; Yaoxing Huang; Lihong Liu; David D Ho
Journal:  Nature       Date:  2022-07-05       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.